The cluster is typical year-end option exercise/vesting activity, not a fundamental signal. Retail investors should not read bearish intent into these sales. Monitor upcoming NBIX earnings (likely early August) for product sales trends, not insider patterns.
NBIX drugs
NBIX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $172.04entry
- T+1 · 4mo ago +0.01%α −0.39% · $172.05
- T+5 · 4mo ago +4.07%α +4.55% · $179.05
- T+20 · 3mo ago −5.87%α −8.36% · $161.94
- T+60 · 6w ago −16.61%α −19.98% · $143.47
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two senior NBIX executives, Chief Legal Officer Darin Lippoldt and Chief Regulatory Officer Ingrid Delaet, exercised and sold a combined ~18,433 shares on July 8-9, 2026, for total open-market proceeds of ~$3.30M. These are routine option-exercise-and-sell transactions typical of executive compensation cycles, not conviction selling; the cluster size ($3.30M) represents ~0.02% of NBIX's $17.5B market cap, well below the materiality threshold.
Key Financial Metrics
Key Facts
- Two C-suite executives exercised derivative options and immediately sold shares in the same two-day window (July 8-9, 2026)
- Chief Legal Officer Lippoldt sold 10,000 shares for net proceeds of ~$1.80M
- Chief Regulatory Officer Delaet sold a total of 11,170 shares (2,737 + 8,433) for net proceeds of ~$2.00M
- Total open-market sale value: ~$3.30M, only 0.02% of $17.5B market cap
- All sales were accompanied by derivative exercises at exercise prices well below market (range: $0 to $103.52 vs. ~$179 market price)
- No open-market purchases in the cluster, net direction is clean selling
Financial Impact
~$3.3M in open-market sales, ~0.02% of market cap, economically trivial
Risk Factors
- Cluster sales could escalate if more C-suite officers sell in the same window, watch for follow-on Form 4 filings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-NBIX-1784009123947 |
Track record
30 reports on NBIX
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
- Nov 2, 202614d ago Press Release Bullish 6/10 No price data
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
- Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers